Loading, Please Wait...
IRVINE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- IRVINE, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Gala Pharmaceutical, Inc. (GLPH), a provider of cannabis testing in Southern California, today announced that it has started construction of its state-of-the-art cannabis testing facility in Long Beach, California.
Gala Pharmaceutical's CEO Dr. Rehman is looking forward to meeting the needs of a market that he describes as under-served. “We want to be the standard in the industry and make sure we play key role in providing quality services to customers in southern California. The launch of our flagship cannabis testing facility should enable Gala Pharmaceutical to significantly benefit from the burgeoning demand from the cannabis market for the testing services needed to bring products to market,” concluded Dr. Rehman.
Medical Cannabis Regulation & Safety Act (“MCRSA”) was signed into law in October 2015, creating 18 license types to cover commercial cultivation, manufacturing, retail sale, transportation, distribution, delivery, and testing of medical cannabis. Type 8 license holders must test for THC, cannabinoids, contaminants, microbiological impurities, and other compounds listed in Business & Professions Code § 19344.
About Gala Pharmaceutical, Inc.
Gala Pharmaceutical, Inc. (GLPH) is a publicly traded company that provides scientific consulting and analytical laboratory services. GLPH looks forward to developing thorough screening technologies for chemical, plant, soil, and liquid composition analysis. Gala aims to provide quality services to a broad spectrum of customers in the agricultural and pharmaceutical industry.
Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company's best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company's public announcements.
18881 Von Karman Ave Suite 1440
Irvine, California 92612